Contact Information


	General Information
	Infectious Disease
	Cancer
	Topical Microbicides
	Immune Modulation and Inflammation


	April 4th 2008: ImQuest scientists present important HIV Microbicide results at Microbicides 2008 in Delhi, India.

	April 1st 2008: ImQuest publishes results of structure activity relationship study with pyrimidinedione HIV inhibitors.

	September 24th 2007: ImQuest Life Sciences announces the appointment of Robert Schooley, M.D. to its Scientific Advisory Board.

	September 21st 2007: ImQuest Life Sciences announces the appointment of David Ho, M.D. to its Scientific Advisory Board.

	September 20th 2007: ImQuest Life Sciences announces the appointment of Richard J. Whitley, M.D. as Chairman of its Scientific Advisory Board.

	April 25th 2007: ImQuest Life Sciences Receives Grant from International Partnership for Microbicides to Develop Novel Microbicide

	April 25th 2006: ImQuest Life Sciences Licenses Piperazine Series of Anti-Cancer Therapeutic Compounds from Samjin Pharmaceutical Co.

Investor information will be added to this page shortly.

For further information contact Mr. Dan Caffoe, Acting Chief Executive Officer.